APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Products

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neuroprotective Products Industry Growth and Trends Forecast to 2032

22 December 2025117 pages

Choose your research edition.

Industry ResearchNeuroprotective Products Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Products Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Neuroprotective Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Products Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Products Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neuroprotective Products market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroprotective Products is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroprotective Products include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Pfizer Inc, GlaxoSmithKline plc., Biogen, AstraZeneca, Sunovion Pharmaceuticals Inc and NeuroVive Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neuroprotective Products market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neuroprotective Products market size, estimates, and forecasts are presented in terms of sales volume (tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuroprotective Products market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuroprotective Products.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neuroprotective Products market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neuroprotective Products Market by Company

Teva Pharmaceutical Industries Ltd

Novartis

Merck KGaA

Pfizer Inc

GlaxoSmithKline plc.

Biogen

AstraZeneca

Sunovion Pharmaceuticals Inc

NeuroVive Pharmaceutical

Neuren Pharmaceuticals

Hikma Pharmaceuticals PLC

Genervon Biopharmaceuticals

Ceregene

Bionure

Bioniz Theraputics.

BHR Pharma

Allon therapeutics

Neuroprotective Products Segment by Type

Cholinesterase inhibitors

NMDA receptor antagonists

Others

Neuroprotective Products Segment by Application

Alzheimer's disease

Multiple sclerosis

Others

Neuroprotective Products Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuroprotective Products manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neuroprotective Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Cholinesterase inhibitors Table 2. Major Company of NMDA receptor antagonists Table 3. Major Company of Others Table 4. Global Neuroprotective Products Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neuroprotective Products Sales by Type (2021-2026) & (tons) Table 6. Global Neuroprotective Products Sales Market Share in Volume by Type (2021-2026) Table 7. Global Neuroprotective Products Sales by Type (2021-2026) & (US$ Million) Table 8. Global Neuroprotective Products Sales Market Share in Value by Type (2021-2026) Table 9. Global Neuroprotective Products Price by Type (2021-2026) & (US$/ton) Table 10. Global Neuroprotective Products Sales by Type (2027-2032) & (tons) Table 11. Global Neuroprotective Products Sales Market Share in Volume by Type (2027-2032) Table 12. Global Neuroprotective Products Sales by Type (2027-2032) & (US$ Million) Table 13. Global Neuroprotective Products Sales Market Share in Value by Type (2027-2032) Table 14. Global Neuroprotective Products Price by Type (2027-2032) & (US$/ton) Table 15. North America Neuroprotective Products Sales by Type (2021-2026) & (tons) Table 16. North America Neuroprotective Products Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Neuroprotective Products Sales by Type (2021-2026) & (tons) Table 18. Europe Neuroprotective Products Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Neuroprotective Products Sales by Type (2021-2026) & (tons) Table 20. Asia-Pacific Neuroprotective Products Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Neuroprotective Products Sales by Type (2021-2026) & (tons) Table 22. Latin America Neuroprotective Products Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Neuroprotective Products Sales by Type (2021-2026) & (tons) Table 24. Middle East and Africa Neuroprotective Products Sales by Type (2021-2026) & (US$ Million) Table 25. Neuroprotective Products Industry Trends Table 26. Neuroprotective Products Industry Drivers Table 27. Neuroprotective Products Industry Opportunities and Challenges Table 28. Neuroprotective Products Industry Restraints Table 29. Global Neuroprotective Products Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Neuroprotective Products Revenue Market Share by Company (2021-2026) Table 31. Global Neuroprotective Products Sales by Company (2021-2026) & (tons) Table 32. Global Neuroprotective Products Sales Share by Company (2021-2026) Table 33. Global Neuroprotective Products Market Price by Company (2021-2026) & (US$/ton) Table 34. Global Neuroprotective Products Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Neuroprotective Products Major Company Production Sites and Headquarters Table 36. Global Neuroprotective Products Company, Product Type & Application Table 37. Global Neuroprotective Products Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Neuroprotective Products by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Neuroprotective Products Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Neuroprotective Products Sales by Region (2021-2026) & (tons) Table 42. Global Neuroprotective Products Sales Market Share in Volume by Region (2021-2026) Table 43. Global Neuroprotective Products Sales by Region (2021-2026) & (US$ Million) Table 44. Global Neuroprotective Products Sales Market Share in Value by Region (2021-2026) Table 45. Global Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 46. Global Neuroprotective Products Sales by Region (2027-2032) & (tons) Table 47. Global Neuroprotective Products Sales Market Share in Volume by Region (2027-2032) Table 48. Global Neuroprotective Products Sales by Region (2027-2032) & (US$ Million) Table 49. Global Neuroprotective Products Sales Market Share in Value by Region (2027-2032) Table 50. Global Neuroprotective Products Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2027-2032) Table 51. Global Neuroprotective Products Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Neuroprotective Products Sales by Application (2021-2026) & (tons) Table 53. Global Neuroprotective Products Sales Market Share in Volume by Application (2021-2026) Table 54. Global Neuroprotective Products Sales by Application (2021-2026) & (US$ Million) Table 55. Global Neuroprotective Products Sales Market Share in Value by Application (2021-2026) Table 56. Global Neuroprotective Products Price by Application (2021-2026) & (US$/ton) Table 57. Global Neuroprotective Products Sales by Application (2027-2032) & (tons) Table 58. Global Neuroprotective Products Sales Market Share in Volume by Application (2027-2032) Table 59. Global Neuroprotective Products Sales by Application (2027-2032) & (US$ Million) Table 60. Global Neuroprotective Products Sales Market Share in Value by Application (2027-2032) Table 61. Global Neuroprotective Products Price by Application (2027-2032) & (US$/ton) Table 62. North America Neuroprotective Products Sales by Application (2021-2026) & (tons) Table 63. North America Neuroprotective Products Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Neuroprotective Products Sales by Application (2021-2026) & (tons) Table 65. Europe Neuroprotective Products Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Neuroprotective Products Sales by Application (2021-2026) & (tons) Table 67. Asia-Pacific Neuroprotective Products Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Neuroprotective Products Sales by Application (2021-2026) & (tons) Table 69. Latin America Neuroprotective Products Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Neuroprotective Products Sales by Application (2021-2026) & (tons) Table 71. Middle East and Africa Neuroprotective Products Sales by Application (2021-2026) & (US$ Million) Table 72. Teva Pharmaceutical Industries Ltd Company Information Table 73. Teva Pharmaceutical Industries Ltd Business Overview Table 74. Teva Pharmaceutical Industries Ltd Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Industries Ltd Neuroprotective Products Product Portfolio Table 76. Teva Pharmaceutical Industries Ltd Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 80. Novartis Neuroprotective Products Product Portfolio Table 81. Novartis Recent Development Table 82. Merck KGaA Company Information Table 83. Merck KGaA Business Overview Table 84. Merck KGaA Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 85. Merck KGaA Neuroprotective Products Product Portfolio Table 86. Merck KGaA Recent Development Table 87. Pfizer Inc Company Information Table 88. Pfizer Inc Business Overview Table 89. Pfizer Inc Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 90. Pfizer Inc Neuroprotective Products Product Portfolio Table 91. Pfizer Inc Recent Development Table 92. GlaxoSmithKline plc. Company Information Table 93. GlaxoSmithKline plc. Business Overview Table 94. GlaxoSmithKline plc. Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 95. GlaxoSmithKline plc. Neuroprotective Products Product Portfolio Table 96. GlaxoSmithKline plc. Recent Development Table 97. Biogen Company Information Table 98. Biogen Business Overview Table 99. Biogen Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 100. Biogen Neuroprotective Products Product Portfolio Table 101. Biogen Recent Development Table 102. AstraZeneca Company Information Table 103. AstraZeneca Business Overview Table 104. AstraZeneca Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 105. AstraZeneca Neuroprotective Products Product Portfolio Table 106. AstraZeneca Recent Development Table 107. Sunovion Pharmaceuticals Inc Company Information Table 108. Sunovion Pharmaceuticals Inc Business Overview Table 109. Sunovion Pharmaceuticals Inc Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 110. Sunovion Pharmaceuticals Inc Neuroprotective Products Product Portfolio Table 111. Sunovion Pharmaceuticals Inc Recent Development Table 112. NeuroVive Pharmaceutical Company Information Table 113. NeuroVive Pharmaceutical Business Overview Table 114. NeuroVive Pharmaceutical Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 115. NeuroVive Pharmaceutical Neuroprotective Products Product Portfolio Table 116. NeuroVive Pharmaceutical Recent Development Table 117. Neuren Pharmaceuticals Company Information Table 118. Neuren Pharmaceuticals Business Overview Table 119. Neuren Pharmaceuticals Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 120. Neuren Pharmaceuticals Neuroprotective Products Product Portfolio Table 121. Neuren Pharmaceuticals Recent Development Table 122. Hikma Pharmaceuticals PLC Company Information Table 123. Hikma Pharmaceuticals PLC Business Overview Table 124. Hikma Pharmaceuticals PLC Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 125. Hikma Pharmaceuticals PLC Neuroprotective Products Product Portfolio Table 126. Hikma Pharmaceuticals PLC Recent Development Table 127. Genervon Biopharmaceuticals Company Information Table 128. Genervon Biopharmaceuticals Business Overview Table 129. Genervon Biopharmaceuticals Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 130. Genervon Biopharmaceuticals Neuroprotective Products Product Portfolio Table 131. Genervon Biopharmaceuticals Recent Development Table 132. Ceregene Company Information Table 133. Ceregene Business Overview Table 134. Ceregene Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 135. Ceregene Neuroprotective Products Product Portfolio Table 136. Ceregene Recent Development Table 137. Bionure Company Information Table 138. Bionure Business Overview Table 139. Bionure Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 140. Bionure Neuroprotective Products Product Portfolio Table 141. Bionure Recent Development Table 142. Bioniz Theraputics. Company Information Table 143. Bioniz Theraputics. Business Overview Table 144. Bioniz Theraputics. Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 145. Bioniz Theraputics. Neuroprotective Products Product Portfolio Table 146. Bioniz Theraputics. Recent Development Table 147. BHR Pharma Company Information Table 148. BHR Pharma Business Overview Table 149. BHR Pharma Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 150. BHR Pharma Neuroprotective Products Product Portfolio Table 151. BHR Pharma Recent Development Table 152. Allon therapeutics Company Information Table 153. Allon therapeutics Business Overview Table 154. Allon therapeutics Neuroprotective Products Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 155. Allon therapeutics Neuroprotective Products Product Portfolio Table 156. Allon therapeutics Recent Development Table 157. North America Neuroprotective Products Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 158. North America Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 159. North America Neuroprotective Products Sales Market Share by Country (2021-2026) Table 160. North America Neuroprotective Products Sales Forecast by Country (2027-2032) & (tons) Table 161. North America Neuroprotective Products Sales Market Share Forecast by Country (2027-2032) Table 162. North America Neuroprotective Products Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. North America Neuroprotective Products Market Size by Country (2021-2026) & (US$ Million) Table 164. North America Neuroprotective Products Market Share by Country (2021-2026) Table 165. North America Neuroprotective Products Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. North America Neuroprotective Products Market Share Forecast by Country (2027-2032) Table 167. Europe Neuroprotective Products Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 168. Europe Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 169. Europe Neuroprotective Products Sales Market Share by Country (2021-2026) Table 170. Europe Neuroprotective Products Sales Forecast by Country (2027-2032) & (tons) Table 171. Europe Neuroprotective Products Sales Market Share Forecast by Country (2027-2032) Table 172. Europe Neuroprotective Products Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Europe Neuroprotective Products Market Size by Country (2021-2026) & (US$ Million) Table 174. Europe Neuroprotective Products Market Share by Country (2021-2026) Table 175. Europe Neuroprotective Products Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Europe Neuroprotective Products Market Share Forecast by Country (2027-2032) Table 177. Asia-Pacific Neuroprotective Products Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 178. Asia-Pacific Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 179. Asia-Pacific Neuroprotective Products Sales Market Share by Country (2021-2026) Table 180. Asia-Pacific Neuroprotective Products Sales Forecast by Country (2027-2032) & (tons) Table 181. Asia-Pacific Neuroprotective Products Sales Market Share Forecast by Country (2027-2032) Table 182. Asia-Pacific Neuroprotective Products Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Asia-Pacific Neuroprotective Products Market Size by Country (2021-2026) & (US$ Million) Table 184. Asia-Pacific Neuroprotective Products Market Share by Country (2021-2026) Table 185. Asia-Pacific Neuroprotective Products Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Asia-Pacific Neuroprotective Products Market Share Forecast by Country (2027-2032) Table 187. Latin America Neuroprotective Products Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 188. Latin America Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 189. Latin America Neuroprotective Products Sales Market Share by Country (2021-2026) Table 190. Latin America Neuroprotective Products Sales Forecast by Country (2027-2032) & (tons) Table 191. Latin America Neuroprotective Products Sales Market Share Forecast by Country (2027-2032) Table 192. Latin America Neuroprotective Products Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 193. Latin America Neuroprotective Products Market Size by Country (2021-2026) & (US$ Million) Table 194. Latin America Neuroprotective Products Market Share by Country (2021-2026) Table 195. Latin America Neuroprotective Products Market Size Forecast by Country (2027-2032) & (US$ Million) Table 196. Latin America Neuroprotective Products Market Share Forecast by Country (2027-2032) Table 197. Middle East and Africa Neuroprotective Products Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 198. Middle East and Africa Neuroprotective Products Sales by Country (2021-2026) & (tons) Table 199. Middle East and Africa Neuroprotective Products Sales Market Share by Country (2021-2026) Table 200. Middle East and Africa Neuroprotective Products Sales Forecast by Country (2027-2032) & (tons) Table 201. Middle East and Africa Neuroprotective Products Sales Market Share Forecast by Country (2027-2032) Table 202. Middle East and Africa Neuroprotective Products Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 203. Middle East and Africa Neuroprotective Products Market Size by Country (2021-2026) & (US$ Million) Table 204. Middle East and Africa Neuroprotective Products Market Share by Country (2021-2026) Table 205. Middle East and Africa Neuroprotective Products Market Size Forecast by Country (2027-2032) & (US$ Million) Table 206. Middle East and Africa Neuroprotective Products Market Share Forecast by Country (2027-2032) Table 207. Key Raw Materials Table 208. Raw Materials Key Suppliers Table 209. Neuroprotective Products Distributors List Table 210. Neuroprotective Products Customers List Table 211. Research Programs/Design for This Report Table 212. Authors List of This Report Table 213. Secondary Sources Table 214. Primary Sources List of Figures Figure 1. Neuroprotective Products Image Figure 2. Global Neuroprotective Products Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Products Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroprotective Products Sales (2021-2032) & (tons) Figure 5. Cholinesterase inhibitors Image Figure 6. Global Cholinesterase inhibitors Sales YoY Growth (2021-2032) & (tons) Figure 7. NMDA receptor antagonists Image Figure 8. Global NMDA receptor antagonists Sales YoY Growth (2021-2032) & (tons) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (tons) Figure 11. Global Neuroprotective Products Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Neuroprotective Products Market Share by Type 2025 VS 2032 Figure 13. North America Neuroprotective Products Sales Market Share in Volume by Type in 2025 Figure 14. North America Neuroprotective Products Sales Market Share in Value by Type in 2025 Figure 15. Europe Neuroprotective Products Sales Market Share in Volume by Type in 2025 Figure 16. Europe Neuroprotective Products Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Neuroprotective Products Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Neuroprotective Products Sales Market Share in Value by Type in 2025 Figure 19. Latin America Neuroprotective Products Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Neuroprotective Products Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Neuroprotective Products Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Neuroprotective Products Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Neuroprotective Products Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Alzheimer's disease Image Figure 26. Global Alzheimer's disease Sales YoY Growth (2021-2032) & (tons) Figure 27. Multiple sclerosis Image Figure 28. Global Multiple sclerosis Sales YoY Growth (2021-2032) & (tons) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (tons) Figure 31. Global Neuroprotective Products Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Neuroprotective Products Market Share by Application 2025 VS 2032 Figure 33. North America Neuroprotective Products Sales Market Share in Volume by Application in 2025 Figure 34. North America Neuroprotective Products Sales Market Share in Value by Application in 2025 Figure 35. Europe Neuroprotective Products Sales Market Share in Volume by Application in 2025 Figure 36. Europe Neuroprotective Products Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Neuroprotective Products Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Neuroprotective Products Sales Market Share in Value by Application in 2025 Figure 39. Latin America Neuroprotective Products Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Neuroprotective Products Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Neuroprotective Products Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Neuroprotective Products Sales Market Share in Value by Application in 2025 Figure 43. North America Neuroprotective Products Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 44. North America Neuroprotective Products Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Neuroprotective Products Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Neuroprotective Products Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 48. Europe Neuroprotective Products Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Neuroprotective Products Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Neuroprotective Products Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 52. Asia-Pacific Neuroprotective Products Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Neuroprotective Products Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Neuroprotective Products Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 56. Latin America Neuroprotective Products Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Neuroprotective Products Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Neuroprotective Products Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 60. Middle East and Africa Neuroprotective Products Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Neuroprotective Products Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Neuroprotective Products Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Neuroprotective Products Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Neuroprotective Products Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Cholinesterase inhibitors
  • NMDA receptor antagonists
  • Others
Applications
  • Alzheimer's disease
  • Multiple sclerosis
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis
  • Merck KGaA
  • Pfizer Inc
  • GlaxoSmithKline plc.
  • Biogen
  • AstraZeneca
  • Sunovion Pharmaceuticals Inc
  • NeuroVive Pharmaceutical
  • Neuren Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Genervon Biopharmaceuticals
  • Ceregene
  • Bionure
  • Bioniz Theraputics.
  • BHR Pharma
  • Allon therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroprotective Products Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neuroprotective Products Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neuroprotective Products Market by Type
  6. 1.3.1 Cholinesterase inhibitors
  7. 1.3.2 NMDA receptor antagonists
  8. 1.3.3 Others
  9. 1.4 Global Neuroprotective Products Market Size by Type
  10. 1.4.1 Global Neuroprotective Products Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Neuroprotective Products Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Neuroprotective Products Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Neuroprotective Products Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Neuroprotective Products Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Neuroprotective Products Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Neuroprotective Products Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Neuroprotective Products Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neuroprotective Products Industry Trends
  2. 2.2 Neuroprotective Products Industry Drivers
  3. 2.3 Neuroprotective Products Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Products Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neuroprotective Products Revenue (2021-2026)
  2. 3.2 Global Top Players by Neuroprotective Products Sales (2021-2026)
  3. 3.3 Global Top Players by Neuroprotective Products Price (2021-2026)
  4. 3.4 Global Neuroprotective Products Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuroprotective Products Major Company Production Sites & Headquarters
  6. 3.6 Global Neuroprotective Products Company, Product Type & Application
  7. 3.7 Global Neuroprotective Products Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuroprotective Products Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuroprotective Products Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuroprotective Products Tier 1, Tier 2, and Tier 3
4 Neuroprotective Products Regional Status and Outlook
  1. 4.1 Global Neuroprotective Products Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neuroprotective Products Historic Market Size by Region
  3. 4.2.1 Global Neuroprotective Products Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neuroprotective Products Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neuroprotective Products Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neuroprotective Products Forecasted Market Size by Region
  7. 4.3.1 Global Neuroprotective Products Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neuroprotective Products Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neuroprotective Products Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neuroprotective Products by Application
  1. 5.1 Neuroprotective Products Market by Application
  2. 5.1.1 Alzheimer's disease
  3. 5.1.2 Multiple sclerosis
  4. 5.1.3 Others
  5. 5.2 Global Neuroprotective Products Market Size by Application
  6. 5.2.1 Global Neuroprotective Products Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Neuroprotective Products Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Neuroprotective Products Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Neuroprotective Products Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Neuroprotective Products Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Neuroprotective Products Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Neuroprotective Products Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Neuroprotective Products Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd
  2. 6.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Products Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Neuroprotective Products Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck KGaA
  14. 6.3.1 Merck KGaA Company Information
  15. 6.3.2 Merck KGaA Business Overview
  16. 6.3.3 Merck KGaA Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck KGaA Neuroprotective Products Product Portfolio
  18. 6.3.5 Merck KGaA Recent Developments
  19. 6.4 Pfizer Inc
  20. 6.4.1 Pfizer Inc Company Information
  21. 6.4.2 Pfizer Inc Business Overview
  22. 6.4.3 Pfizer Inc Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Inc Neuroprotective Products Product Portfolio
  24. 6.4.5 Pfizer Inc Recent Developments
  25. 6.5 GlaxoSmithKline plc.
  26. 6.5.1 GlaxoSmithKline plc. Company Information
  27. 6.5.2 GlaxoSmithKline plc. Business Overview
  28. 6.5.3 GlaxoSmithKline plc. Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 GlaxoSmithKline plc. Neuroprotective Products Product Portfolio
  30. 6.5.5 GlaxoSmithKline plc. Recent Developments
  31. 6.6 Biogen
  32. 6.6.1 Biogen Company Information
  33. 6.6.2 Biogen Business Overview
  34. 6.6.3 Biogen Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Biogen Neuroprotective Products Product Portfolio
  36. 6.6.5 Biogen Recent Developments
  37. 6.7 AstraZeneca
  38. 6.7.1 AstraZeneca Company Information
  39. 6.7.2 AstraZeneca Business Overview
  40. 6.7.3 AstraZeneca Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 AstraZeneca Neuroprotective Products Product Portfolio
  42. 6.7.5 AstraZeneca Recent Developments
  43. 6.8 Sunovion Pharmaceuticals Inc
  44. 6.8.1 Sunovion Pharmaceuticals Inc Company Information
  45. 6.8.2 Sunovion Pharmaceuticals Inc Business Overview
  46. 6.8.3 Sunovion Pharmaceuticals Inc Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sunovion Pharmaceuticals Inc Neuroprotective Products Product Portfolio
  48. 6.8.5 Sunovion Pharmaceuticals Inc Recent Developments
  49. 6.9 NeuroVive Pharmaceutical
  50. 6.9.1 NeuroVive Pharmaceutical Company Information
  51. 6.9.2 NeuroVive Pharmaceutical Business Overview
  52. 6.9.3 NeuroVive Pharmaceutical Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 NeuroVive Pharmaceutical Neuroprotective Products Product Portfolio
  54. 6.9.5 NeuroVive Pharmaceutical Recent Developments
  55. 6.10 Neuren Pharmaceuticals
  56. 6.10.1 Neuren Pharmaceuticals Company Information
  57. 6.10.2 Neuren Pharmaceuticals Business Overview
  58. 6.10.3 Neuren Pharmaceuticals Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Neuren Pharmaceuticals Neuroprotective Products Product Portfolio
  60. 6.10.5 Neuren Pharmaceuticals Recent Developments
  61. 6.11 Hikma Pharmaceuticals PLC
  62. 6.11.1 Hikma Pharmaceuticals PLC Company Information
  63. 6.11.2 Hikma Pharmaceuticals PLC Business Overview
  64. 6.11.3 Hikma Pharmaceuticals PLC Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Hikma Pharmaceuticals PLC Neuroprotective Products Product Portfolio
  66. 6.11.5 Hikma Pharmaceuticals PLC Recent Developments
  67. 6.12 Genervon Biopharmaceuticals
  68. 6.12.1 Genervon Biopharmaceuticals Company Information
  69. 6.12.2 Genervon Biopharmaceuticals Business Overview
  70. 6.12.3 Genervon Biopharmaceuticals Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Genervon Biopharmaceuticals Neuroprotective Products Product Portfolio
  72. 6.12.5 Genervon Biopharmaceuticals Recent Developments
  73. 6.13 Ceregene
  74. 6.13.1 Ceregene Company Information
  75. 6.13.2 Ceregene Business Overview
  76. 6.13.3 Ceregene Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Ceregene Neuroprotective Products Product Portfolio
  78. 6.13.5 Ceregene Recent Developments
  79. 6.14 Bionure
  80. 6.14.1 Bionure Company Information
  81. 6.14.2 Bionure Business Overview
  82. 6.14.3 Bionure Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Bionure Neuroprotective Products Product Portfolio
  84. 6.14.5 Bionure Recent Developments
  85. 6.15 Bioniz Theraputics.
  86. 6.15.1 Bioniz Theraputics. Company Information
  87. 6.15.2 Bioniz Theraputics. Business Overview
  88. 6.15.3 Bioniz Theraputics. Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Bioniz Theraputics. Neuroprotective Products Product Portfolio
  90. 6.15.5 Bioniz Theraputics. Recent Developments
  91. 6.16 BHR Pharma
  92. 6.16.1 BHR Pharma Company Information
  93. 6.16.2 BHR Pharma Business Overview
  94. 6.16.3 BHR Pharma Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 BHR Pharma Neuroprotective Products Product Portfolio
  96. 6.16.5 BHR Pharma Recent Developments
  97. 6.17 Allon therapeutics
  98. 6.17.1 Allon therapeutics Company Information
  99. 6.17.2 Allon therapeutics Business Overview
  100. 6.17.3 Allon therapeutics Neuroprotective Products Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Allon therapeutics Neuroprotective Products Product Portfolio
  102. 6.17.5 Allon therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America Neuroprotective Products Sales by Country
  2. 7.1.1 North America Neuroprotective Products Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neuroprotective Products Sales by Country (2021-2026)
  4. 7.1.3 North America Neuroprotective Products Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neuroprotective Products Market Size by Country
  6. 7.2.1 North America Neuroprotective Products Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neuroprotective Products Market Size by Country (2021-2026)
  8. 7.2.3 North America Neuroprotective Products Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neuroprotective Products Sales by Country
  2. 8.1.1 Europe Neuroprotective Products Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neuroprotective Products Sales by Country (2021-2026)
  4. 8.1.3 Europe Neuroprotective Products Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neuroprotective Products Market Size by Country
  6. 8.2.1 Europe Neuroprotective Products Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neuroprotective Products Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neuroprotective Products Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neuroprotective Products Sales by Country
  2. 9.1.1 Asia-Pacific Neuroprotective Products Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neuroprotective Products Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neuroprotective Products Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neuroprotective Products Market Size by Country
  6. 9.2.1 Asia-Pacific Neuroprotective Products Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neuroprotective Products Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neuroprotective Products Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neuroprotective Products Sales by Country
  2. 10.1.1 South America Neuroprotective Products Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neuroprotective Products Sales by Country (2021-2026)
  4. 10.1.3 South America Neuroprotective Products Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neuroprotective Products Market Size by Country
  6. 10.2.1 South America Neuroprotective Products Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neuroprotective Products Market Size by Country (2021-2026)
  8. 10.2.3 South America Neuroprotective Products Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neuroprotective Products Sales by Country
  2. 11.1.1 Middle East and Africa Neuroprotective Products Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neuroprotective Products Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neuroprotective Products Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neuroprotective Products Market Size by Country
  6. 11.2.1 Middle East and Africa Neuroprotective Products Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neuroprotective Products Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neuroprotective Products Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neuroprotective Products Value Chain Analysis
  2. 12.1.1 Neuroprotective Products Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neuroprotective Products Production Mode & Process
  7. 12.2 Neuroprotective Products Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neuroprotective Products Distributors
  10. 12.2.3 Neuroprotective Products Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst